The Randox direct sd LDL measurement is fully automated, saving time and labour costs and gives quantitative sdLDL values, that will enable treatment optimisation
Randox has released a simple test for fully automated clinical chemistry analysers for the quantitative detection of sd LDL cholesterol.
Research has shown that the small dense form of LDL (sd LDL) cholesterol carries a three fold increased risk of myocardial infarction compared to large LDL cholesterol.
Research into LDL cholesterol and the implications for risk of cardiovascular disease (CVD) has identified two LDL subtypes, small dense and large buoyant LDL.
Genetic and nutritional factors affect the size of the LDL particles.
The small, more atherogenic LDL particles penetrate the inner layer of the coronary arteries more easily, are more susceptible to oxidisation and bind proteoglycans, all of which increase the risk of CVD.
Determination of sd LDL in a patient sample can help clinicians profile higher risk individuals and improve prognosis through adjusted treatment.
This test is now being used in routine lipid laboratories.
Randox has widened the range of lipoprotein tests by releasing a simple method for sd LDL.
It can be run on an automated clinical chemistry analyser, and will give results in 30 minutes.
This method supersedes the current electrophoresis method, which assesses the pattern of LDL to identify type A (predominantly large LDL) or type B (predominantly small LDL).
This is time consuming, requires specialist equipment and operators and gives only qualitative results.
Randox is an international diagnostics company, headquartered in Northern Ireland.
Randox develops, manufactures and markets clinical diagnostic products worldwide.
Core products are: Biochip Array Technology; clinical chemistry analysers and reagents; quality controls and EQA; environmental diagnostics; antibodies and recombinant proteins for life sciences.
